AC Immune SA (ACIU)

Sep 26, 2026

AC Immune's Phase II VacSYn trial for a Parkinson's vaccine, ACI-7104.056, successfully met its primary safety, tolerability, and immunogenicity goals. The study showed that all treated participants developed antibodies against aggregated alpha-synuclein, with detectable levels in cerebrospinal fluid. The company plans further development, including quarterly dosing studies and a larger Part 2 trial, to investigate potential disease-modifying effects.

Sep 23, 2026

AC Immune (NASDAQ: ACIU) announced that its investigational Parkinson's drug, ACI-7104, demonstrated 100% antibody response and was safe and well-tolerated in Part 1 of its Phase 2 VacSYn clinical trial. The company plans to refine its development approach and discuss next steps with regulators before moving to an expanded Phase 2 trial to establish clinical activity for entry into Phase 3. Exploratory analyses also showed preliminary evidence of target engagement and positive trends between immunogenicity antibody levels and disease activity measures.